Last reviewed · How we verify

NCT03295656

Contrast-Enhanced Ultrasound Diagnosis of Acute Appendicitis

Withdrawn Phase 1 Last updated 17 July 2020
What this trial tests

Phase 1 trial testing Sulfur hexafluoride lipid-type A microspheres in Appendicitis Acute. Withdrawn.

Timeline
15 July 2020
Primary endpoint
15 July 2020
15 July 2020

Quick facts

Lead sponsorBoston Children's Hospital
PhasePhase 1
StatusWithdrawn
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposediagnostic
Start date15 July 2020
Primary completion15 July 2020
Estimated completion15 July 2020
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Boston Children's Hospital

Who can join

Adults 8 to 17, any sex, with Appendicitis Acute. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study evaluates the ability of contrast-enhanced ultrasound to improve the diagnosis of acute appendicitis in children compared to conventional ultrasound.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Sulfur hexafluoride lipid-type A microspheres

Trials testing the same drug.

Other recruiting trials for Appendicitis Acute

Currently open trials in the same condition.

Other Boston Children's Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03295656.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing